As the exclusive Presenting Sponsor of all General Sessions, your company will receive premier visibility during the most highly attended, unopposed sessions of the ASGCT Annual Meeting. These cornerstone General Sessions feature keynote speakers, distinguished award winners, and set the tone for the entire conference.

This elite sponsorship includes:

• Verbal recognition by ASGCT leadership during each General Session

  • George Stamatoyannopoulos Memorial Lecture

  • Founders, Catalyst, and Mendell Award Symposium

  • Outstanding New Investigator Symposium

  • Presidential Symposium

• Prominent brand placement with a static banner ad displayed in the rotating pre-session slides

• Logo visibility on the virtual platform’s session viewing pages

• Featured placement in the conference’s Schedule at a Glance

Each General Session offers an exclusive opportunity to sponsor one of the most highly attended and unopposed presentations at the Annual Meeting, featuring premier keynote speakers and distinguished award recipients.

Sponsorship includes:

• Verbal recognition by ASGCT during the sponsored session

• Opportunity to display a static banner ad in the rotating pre-session slides

• Company logo placement on the session viewing page within the virtual platform

• Logo inclusion in the online Schedule-at-Glance

2025 Keynote Speakers of the George Stamatoyannopoulos Memorial Symposium:

• Kiran Musunuru, MD, PhD
  Kiran Musunuru, MD, PhD, MPH, ML, is Professor of Cardiovascular Medicine and Genetics in the Perelman School of Medicine at the University of Pennsylvania. His research focuses on the genetics of heart disease and seeks to identify genetic factors that protect against disease and use them to develop new therapies.
   
• Tippi C. MacKenzie, MD
  Tippi MacKenzie, MD, is a pediatric and fetal surgeon at the University of California, San Francisco, and Director of the Broad Stem Cell Center. Her lab examines fetal biology and maternal-fetal tolerance with the goal of developing new fetal therapies for patients with genetic diseases or pregnancy complications. She has moved two fetal molecular therapies from the laboratory to the clinic as FDA-approved phase 1 clinical trials: in utero hematopoietic stem cell transplantation to treat fetuses with alpha thalassemia and in utero enzyme replacement therapy to treat fetuses with lysosomal storage disorders. Her ongoing research is focused on developing prenatal somatic cell gene therapies using antisense oligonucleotides, gene therapy and genome editing. 

Each General Session offers an exclusive opportunity to sponsor one of the most highly attended and unopposed presentations at the Annual Meeting, featuring premier keynote speakers and distinguished award recipients.

Sponsorship includes:

• Verbal recognition by ASGCT during the sponsored session

• Opportunity to display a static banner ad in the rotating pre-session slides

• Company logo placement on the session viewing page within the virtual platform

• Logo inclusion in the online Schedule-at-Glance

Each General Session offers an exclusive opportunity to sponsor one of the most highly attended and unopposed presentations at the Annual Meeting, featuring premier keynote speakers and distinguished award recipients.

Sponsorship includes:

• Verbal recognition by ASGCT during the sponsored session

• Opportunity to display a static banner ad in the rotating pre-session slides

• Company logo placement on the session viewing page within the virtual platform

• Logo inclusion in the online Schedule-at-Glance

2025 Keynote Speakers of the Presidential Symposium:

• Drew Weissman, MD, PhD
  AI-generated content may be incorrect.Drew Weissman, MD, PhD, is a world-renowned physician and researcher at Penn Medicine, best known for his contributions to RNA biology and the COVID-19 vaccines. Weissman and Katalin Karikó, PhD, were jointly awarded the 2023 Nobel Prize in Medicine for their discoveries that enabled the modified mRNA technology being used in Pfizer-BioNTech and Moderna's vaccines to prevent COVID-19.
• Mike McCune, MD, PhD
  Mike McCune, MD, PhD, is head of the HIV Frontiers Program at the Gates Foundation, best known for his contributions to understanding HIV pathogenesis and for the invention of humanized mice. Prior to joining the foundation in 2018, Dr. McCune was chief of the division of experimental medicine at the University of California, San Francisco. He also co-founded the companies SyStemix (1988) and Progenesys (1991), leading research efforts to develop antiviral medications and hematopoietic stem cell-based gene therapies for the treatment of HIV disease.

2024 Keynote Speakers of the Presidential Symposium:

• Kevin Campbell, PhD, University of Iowa 
  Dr. Campbell is a professor, Roy J. Carver Biomedical Research Chair in Molecular Physiology and Biophysics, and director of the Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center at the University of Iowa's Carver College of Medicine. He's also an investigator at the Howard Hughes Medical Institute. Research in Dr. Campbell's lab is focused on the mechanism of muscular dystrophies and development of therapeutic strategies to treat muscular dystrophy. His studies on dystroglycan have since led to significant insights into its basic function as an extracellular matrix receptor in skeletal muscle, its role in the maintenance of muscle-cell membrane integrity, and its role in the molecular pathogenesis of glycosylation deficient muscular dystrophy. 
   
• Charles Murry, MD, PhD, University of Washington Medicine 
  Dr. Murry is a professor as well as the William and Marilyn Conner Chair and director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington School of Medicine. He is a cardiovascular pathologist whose clinical interests span ischemic heart disease, cardiac transplantation, atherosclerosis, heart failure, cardiomyopathy, valvular disease, and non-atherosclerotic vascular disease. The Murry lab is a multidisciplinary group, spanning molecular regulation of stem cell differentiation, animal models of disease, and studies of human tissue. The lab has a longstanding interest in the biology of myocardial infarction (heart attack), with the goal of harnessing stem cells to promote regeneration of heart muscle and the coronary circulation. (Photo courtesy of the University of Washington) 

Each General Session offers an exclusive opportunity to sponsor one of the most highly attended and unopposed presentations at the Annual Meeting, featuring premier keynote speakers and distinguished award recipients.

Sponsorship includes:

• Verbal recognition by ASGCT during the sponsored session

• Opportunity to display a static banner ad in the rotating pre-session slides

• Company logo placement on the session viewing page within the virtual platform

• Logo inclusion in the online Schedule-at-Glance

Kick off #ASGCT2026 with high-impact education!
Workshops will launch the Annual Meeting on Monday, May 11, offering attendees the opportunity to dive deep into specialized topics ahead of the main program. Support these sessions and boost your brand visibility across all workshops!

Sponsorship Benefits:

• Company logo (scaled to 50%) featured on meter board signage on May 11 recognizing all workshop sponsors

2025 Topics Included (2026 topics to be announced in December!):

• Gene Editing

• AAV/Vector Manufacturing

• CAR-T & Immune Effectors

• Patient Engagement

• CMC Regulatory Issues

• Nonclinical Pathway to Clinical Trials for AAV-Based Therapeutics

Kick off #ASGCT2026 with high-impact education!
Workshops will launch the Annual Meeting on Monday, May 11, offering attendees the opportunity to dive deep into specialized topics ahead of the main program. Support these sessions and boost your brand visibility across all workshops!

Sponsorship Benefits:

• Company logo (scaled to 100%) featured on meter board signage on May 11 recognizing all workshop sponsors

2025 Topics Included (2026 topics to be announced in December!):

• Gene Editing

• AAV/Vector Manufacturing

• CAR-T & Immune Effectors

• Patient Engagement

• CMC Regulatory Issues

• Nonclinical Pathway to Clinical Trials for AAV-Based Therapeutics